Current overview and special considerations for second breast cancer in Hodgkin lymphoma survivors

Bakkach, Joaira; Pellegrino, Benedetta; Elghazawy, Hagar; Novosad, O.; Agrawal, Sanjit Kumar; Mechita, Mohcine Bennani

doi:10.1016/j.critrevonc.2020.103175

Cited by 8 publications

(6 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, after multidisciplinary consultation, mastectomy was advised because breast radiotherapy would technically complicate lymphoma radiotherapy due to partial overlapping of radiation fields and because of an increased risk of secondary breast cancer in HL survivors after thoracic radiotherapy. The cumulative incidence of secondary breast cancer in HL survivors by the age of 50 is 35% with the most important risk factor being younger age at treatment ( Bakkach et al, November 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Charlotte

Dierickx

Wildiers

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Highlights This is the first reported case of two concurrent primary cancers during pregnancy. The multidisciplinary tumor board was critical in defining the best treatment. Modifications to the standard-of-care should always be motivated. Both cancers were treated during pregnancy with surgery and chemotherapy. The result was a good maternal and obstetric outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Charlotte

Dierickx

Wildiers

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

“…In the current study, a large fraction (41%) of secondary BCs occurred in CCS previously diagnosed with Hodgkin lymphoma. It is well documented that CCS, particularly Hodgkin's survivors, are at elevated risk of early onset secondary BC, which has been attributed to thoracic radiation or alkylating chemotherapies 12,22‐24 . Recently, consensus recommendations were issued for annual BC screening beginning at age 25 or 8 years after radiation in female CCS who received at least 10 grays (Gy) of thoracic radiation 19 .…”

Section: Discussionmentioning

confidence: 99%

Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer

Lynch

Kane

Fleming

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background Childhood cancer survivors (CCS) are at elevated risk of secondary malignancies (SM). Enhanced screening for SM is recommended, but compliance is poor. We hypothesized that CCS with adult‐onset SM (colorectal cancer [CRC], melanoma, or breast cancer [BC]) would present with more advanced disease and have decreased overall survival (OS). Methods The Surveillance, Epidemiology, and End Results Program was queried for patients diagnosed with cancer at age less than or equal to 18 also diagnosed with adult‐onset CRC, melanoma, or BC. A cohort without a history of prior malignancy was likewise identified. Tumor features and clinical outcomes were compared. Results CCS with a SM (n = 224) were compared with patients without a childhood cancer history (n = 1,392,670). CCS were diagnosed younger (BC = 37.6 vs. 61.3, p < 0.01, CRC = 35.0 vs. 67.1, p < 0.01, melanoma = 29.6 vs. 61.3 years old, p < 0.01). CCS with BC were more likely to have Stage III or IV disease (25.2% vs. 16.5%, p = 0.01). Hormone‐receptor expression also differed; CCS were less likely to develop Luminal A‐type tumors (48.6% vs. 66.9%, p = 0.01). After age‐adjustment, CCS had worse OS (Hazard ratio: CRC = 2.449, p < 0.01, melanoma = 6.503, p < 0.01, BC = 3.383, p < 0.01). Conclusion CCS were younger when diagnosed with a SM. After age‐adjustment, OS was diminished. Heightened surveillance may be necessary for CCS diagnosed with SM.

show abstract

“…The literature about the HSCT-related SMNs has been reviewed in detail recently [ 47 ]. In lymphoma survivors, solid cancers including breast cancer, thyroid cancer, lung cancer, gastrointestinal cancers, and sarcomas [ 48 , 49 ] account for the majority of SMNs, while the most common SMN in HL survivors is secondary breast cancer [ 50 , 51 ]. Accumulating evidence suggests that the therapy-related risk of SMNs increases after a delay of about 10 to 15 years and depends on age at treatment, patient characteristics, differences in radiotherapy and chemotherapy, radiation dose, and length of follow-up [ 52 ].…”

Section: Lymphomas and Second Malignant Neoplasmsmentioning

confidence: 99%

“…While high-doses, intermediate-doses, and low-doses radiotherapy showed inconsistent results, assessing the doses being delivered should consider multiple variable parameters such as patient height, weight, size, volume and shape of the tumor, irradiation modalities, etc. The inconsistent results were also found in the chemotherapy when assessing the risk of SMNs because chemotherapy regimens could not be as a sole modality for lymphoma therapy [ 50 , 51 ]. Likewise, multiple variable parameters as aforementioned should considered to assess the late effects of chemotherapy in lymphoma patients.…”

Section: Lymphomas and Second Malignant Neoplasmsmentioning

confidence: 99%

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases

Shi

Wang

et al. 2022

Cell Biosci

View full text Add to dashboard Cite

With inconsistent findings, evidence has been obtained in recent years that metabolic disorders are closely associated with the development of lymphomas. Studies and multiple analyses have been published also indicating that some solid tumor survivors develop a secondary lymphoma, whereas some lymphoma survivors subsequently develop a second malignant neoplasm (SMN), particularly solid tumors. An interaction between the multiple etiologic factors such as genetic factors and late effects of cancer therapy may play an important role contributing to the carcinogenesis in patients with metabolic diseases or with a primary cancer. In this review, we summarize the current knowledge of the multiple etiologic factors for lymphomagenesis, focusing on the SMN in lymphoma, secondary lymphomas in primary cancers, and the lymphomas associated to metabolic disorders/diseases, which have been received less attention previously. Further, we also review the data of coexistence of lymphomas and hepatocellular carcinoma (HCC) in patients with infection of hepatitis C virus and hepatitis B virus. Graphical Abstract

show abstract

Current overview and special considerations for second breast cancer in Hodgkin lymphoma survivors

Cited by 8 publications

References 93 publications

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases

Contact Info

Product

Resources

About